News & Updates

Show Multimedia Only
Empagliflozin benefits similar between MRA users, nonusers

Empagliflozin benefits similar between MRA users, nonusers

31 Mar 2022

In patients with heart failure (HF) and preserved ejection fraction, treatment with empagliflozin delivers comparable benefits in reducing first hospitalization for HF or cardiovascular death (primary outcome) between users and nonusers of mineralocorticoid receptor antagonists (MRA), reports a study.

31 Mar 2022